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612Objective: We used a population-based cancer registry to examine the association between lymph node counts
and mortality to determine the minimum number of lymph nodes that should be examined as part of esophageal
resection.
Methods: Using the Surveillance Epidemiology and End Results database, we identified patients who had an
esophagectomy for invasive esophageal carcinoma from 1988 through 2005 and who had a known number of
lymph nodes examined pathologically. After stratifying patients (0, 1–11, 12–29, and 30 or more lymph nodes
examined) based on a recursive partitioning analysis, we assessed the association between lymph nodes counts
and mortality using the Kaplan-Meier method. To adjust for potential confounding covariates, we used a Cox
proportional hazards regression model.
Results: Of the patients in the Surveillance Epidemiology and End Results database with esophageal cancer, 4882
met our inclusion criteria. We noted a significant difference between the lymph node groups with regards to unad-
justed all-cause (P< .0001) and cancer-specific mortality (P ¼ .004). After adjusting for cancer registry, patient
factors, tumor characteristics, and timing of radiation therapy, we noted a significant difference between the lymph
node groupswith regards to all-cause and cancer-specificmortality.Comparedwith patientswhohadno lymphnode
evaluation, only patients who hadmore than 12 lymph nodes examined had a significant improvement in mortality;
patients who had 30 or more lymph nodes examined had significantly lower mortality rates than the other groups.
Conclusion: To maximize all-cause and cancer-specific survival, esophageal cancer patients should have at least
30 lymph nodes examined pathologically as part of esophageal resection. (J Thorac Cardiovasc Surg 2010;139:
612-20)Earn CME credits at
http://cme.ctsnetjournals.org
Accurate esophageal cancer staging has important prognos-
tic and therapeutic implications, yet there is no standard of
care regarding the minimum number of lymph nodes
(LNs) that should be removed during esophagectomy and
examined by the pathologist.
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ascertain if this number is the same as the minimum number
of LNs needed for accurate nodal staging. We hypothesized
that (1) higher total LN counts are associated with improved
survival to a point, after which higher counts confer no
significant incremental improvement in survival and (2)
the minimum number of LNs needed to maximize survival
is different than the minimum number needed for accurate
cancer staging.
METHODS
The Human Subjects Committee of the University of
Minnesota determined that this study was exempt from for-
mal review by the Institutional Review Board.
Data
The Surveillance, Epidemiology, and End Results (SEER)
database is a population-based cancer registry that was
founded in 1973 by the National Cancer Institute (Bethesda,
Md). Currently, 17 US cancer registries, selected to encom-
pass a diverse sample (about 26%) of the national population,
participate in the SEERProgram.We used the SEERdatabase
that was based on the November 2007 submission, which
provides data through December 31, 2005.1 SEER registriesery c March 2010
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AJCC ¼ American Joint Committee on Cancer
CI ¼ confidence interval
GEJ ¼ gastroesophageal junction
LN ¼ lymph node
OR ¼ odds ratioSSEER ¼TSurveillance, Epidemiology, and End
ResultsGbegan collecting LN data in 1988; therefore, this study rep-
resents data collected by the SEER registries from 1988
through 2005. Because of the negative impact of Hurricane
Katrina on data collection by the Louisiana SEER registry,
we excluded information obtained by that registry in 2005.
We collected information on patient characteristics,
primary tumor characteristics, and treatment regimens.
Inclusion Criteria
We selected patients from the SEER database for inclu-
sion in our study using the following International Classifi-
cation Disease for Oncology, 3rd Edition (ICD-O3)2
topography codes (in parenthesis) for each anatomic loca-
tion in the esophagus: proximal esophagus (15.0 and 15.3;
lower border of the cricoid cartilage to the tracheal bifurca-
tion), midthoracic esophagus (15.1 and 15.4; tracheal bifur-
cation midway to the gastroesophageal junction [GEJ]),
distal esophagus (15.2 and 15.5; midway to the GEJ to the
GEJ), overlapping lesions (15.8) and esophageal lesions,
not otherwise specified (15.9).
We only included patients over the age of 18 who had an
esophagectomy for invasive esophageal carcinoma and who
had a known number of LNs examined (pathologically). The
following carcinoma histologic subtypes were included in
our analysis (ICD-O3 morphology codes in parenthesis)
and were categorized as follows: (1) adenocarcinomas: pap-
illary carcinoma, not otherwise specified (8050–8052), basa-
loid carcinoma (8123), adenocarcinoma (8140–8147),
adenocarcinoma in an adenomatous polyp (8210), tubular
adenocarcinoma (8211), adenocarcinoma with mixed sub-
types (8255), papillary adenocarcinoma (8260–8263), clear
cell adenocarcinoma (8310), mucinous adenocarcinoma
(8480–8481), signet cell carcinoma (8490), acinar adenocar-
cinoma (8550), and adenocarcinoma with other features
(8570–8575); (2) squamous cell carcinomas: spindle cell
carcinoma (8032), squamous cell carcinoma (8070–8077),
basaloid squamous carcinoma (8083), and basosquamous
cell carcinoma (8094).
Exclusion Criteria
We excluded patients with more than 1 primary tumor.
Due to the potential for confounding, we also excluded those
patients who were unlikely to have received aggressiveThe Journal of Thoracic and Cacancer treatment: patients with metastatic disease and pa-
tients with a hospice, nursing home, autopsy, or death certif-
icate as their only reporting source.
Statistical Analysis
Data were analyzed using SAS version 9.1 (SAS Institute,
Cary, NC). For all statistical testing, we used a 2-sided sig-
nificance level (alpha) of .05. We stratified patients into LN
groups with homogenous survival using a recursive parti-
tioning analysis based on the log-rank statistic.3 A sensitiv-
ity analysis was performed to confirm that our choice of cut
points did not change our study findings. Descriptive statis-
tics were collected. Where appropriate, results are reported
as mean  standard deviation for normally distributed vari-
ables and median (range in parenthesis) for nonparametric
variables. Between-group comparisons were made using
a 2-sample t test or an analysis of variance for normally
distributed continuous variables, a Wilcoxon rank-sum or
Kruskal-Wallis test for nonparametric continuous variables,
and a chi-square test for categorical variables.
To compare unadjusted all-cause mortality (death from
any cause) and cancer-specific mortality rates (death from
cancer) between each LN group, we used the Kaplan-Meier
method. We adjusted for the following potential confound-
ing covariates using a Cox proportional hazards regression
model: patient characteristics (age, race, and gender), geo-
graphical location (cancer registry), tumor characteristics
(histology, grade, American Joint Committee on Cancer
[AJCC] pathological T stage,4 and anatomic location), and
timing of radiation therapy.With the exception of pathologic
T stage, all of the covariates are known to a surgeon prior to
esophagectomy. Because of a lack of longer-term follow-up
(12% of our cohort), we censored our survival analyses at 5
years. After testing the proportional hazards assumption, we
generated log-log survival plots to subjectively assess homo-
geneity of the hazard ratios over time. After adjusting alpha
using the Bonferroni correction, we used a multiple compar-
isons test to compare hazard ratios between LN groups. We
validated our model by taking out a 33% random sample of
our cohort and repeating our survival analysis.
Total LN counts (our principal explanatory variable) are
highly correlated with the number of positive LNs, which
in turn are highly correlated with N stage. Therefore, we
did not include number of positive LNs (or N stage) in our
model to avoid multicollinearity (which could reduce the
precision of our model). Instead, we adjusted for the poten-
tial confounding influence of LN metastasis by performing
a stratified survival analysis.We also assessed for interaction
between other tumor characteristics (ie, T stage, histology,
and grade) and LN counts. Due to concern for interaction be-
tween LN counts and timing of radiation therapy, we also
stratified our results by timing of radiation therapy. We hy-
pothesized that neoadjuvant radiation therapy was associ-
ated with lower LN counts.rdiovascular Surgery c Volume 139, Number 3 613
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dichotomizes nodal status: N0 (absence of LN metastasis)
and N1 (presence of LN metastasis). Therefore, to assess
whether the number of LNs needed to optimize survival
was consistent with the number needed to optimize accurate
nodal staging, we plotted the frequency of patients with at
least 1 positive LN for each LN count using locally weighted
least squares smoothing. We compared to odds of finding
LN metastasis in each LN group using a logistic regression
model adjusted for the same covariates as the Cox propor-
tional hazards regression model.
RESULTS
Descriptive Statistics
Of 7323 patients in the SEER database (1988–2005) who
had an esophagectomy for invasive esophageal cancer and
had a known number of LNs examined, 4882 met our inclu-
sion criteria (Figure 1). Patients who had an esophagectomy
and had a known number of LNs examined that we excludedInvasive Esophageal Cancer
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FIGURE 1. Patients included i
614 The Journal of Thoracic and Cardiovascular Surgfrom our study were more likely to be older, to have an un-
known T stage, an undifferentiated or unknown grade, and
more positive LNs. They also had fewer LNs examined
and were less likely to undergo radiation therapy (Table 1).
Patients who were included in our study did not have signif-
icantly different all-cause (log-rank, P¼ .43) or cancer-spe-
cific (log-rank, P ¼ .56) survival rates than patients who we
excluded, suggesting that selection bias had a minimal im-
pact on our results.
A recursive partitioning survival tree analysis identified
the following LN groups with significantly differently sur-
vival rates: 0, 1 to 11, 12 to 29, and 30 or more LNs exam-
ined. These groups were used in our survival analysis. There
were significant differences between LN groups with re-
gards to number of potentially important prognostic factors:
age, race, geographic location (SEER registry), tumor grade,
tumor location, tumor histology, T stage, and timing of radi-
ation therapy (Table 2). We adjusted for these variables in
our multivariate survival analysis. Did Not Undergo Esophagectomy
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TABLE 1. Characteristics of patients included versus patients
excluded from inclusion in our study*
Variable Patients included Patients excluded P value
Number of patients 4882 2667
Age at diagnosis (y) 62.5  10.3 64.7  10.4 <.0001
Race (%) .42
Caucasian 87.0 86.8
African-American 7.9 8.5
Other 5.1 4.7
Gender (%) .35
Men 81.1 80.2
Women 18.9 19.8
Tumor location (%) <.0001
Proximal 3.5 6.3
Midthoracic 18.4 18.3
Distal 71.0 66.1
Overlapping 3.4 3.3
Unknown 3.7 6.0
Histology (%) <.0001
Adenocarcinoma 67.9 52.7
Squamous cell
carcinoma
32.1 33.1
Other 0 14.2
Grade (%) <.0001
Well differentiated 6.5 4.9
Moderately
differentiated
37.2 30.9
Poorly
differentiated
45.4 40.5
Undifferentiated 2.0 3.8
Unknown 8.9 19.9
T stage (%) <.0001
T1 21.1 18.5
T2 16.8 16.0
T3 36.8 30.5
T4 12.1 11.1
Unknown 13.2 23.9
Median number
of nodes examined
7 (range, 0–90) 5 (range, 0–90) <.0001
Median number
of positive
nodes retrieved
0 (range, 0–35) 0 (range, 0–46) .56
Timing of radiation
therapy (%)
<.0001
None 53.4 61.1
Preoperative 30.4 24.8
Postoperative 16.2 14.1
*Groups did not differ significantly by cancer registry (P ¼ .62; data not shown).
TABLE 2. Characteristics of patients included in our study
Number of lymph nodes examined
0 1 to 11 12 to 29 30 P value*
Number of patients 906 2555 1263 158
Age at diagnosis (y),% .0019
<50 21.1 47.3 28.2 3.4
50–64 19.4 50.1 26.9 3.6
 65 17.1 55.7 24.4 2.8
Race (%) .0002
Caucasian 17.8 52.7 26.3 3.2
African-American 26.9 51.7 18.5 2.9
Other 19.2 47.6 29.2 4.0
Gender (%) .21
Men 18.3 52.4 26.3 3.0
Women 19.8 52.1 24.1 4.0
Tumor location in
esophagus (%)
<.0001
Proximal 28.9 43.9 20.2 6.4
Midthoracic 22.9 51.8 22.5 2.8
Distal 16.3 53.0 27.6 3.1
Overlapping 26.7 46.0 20.0 7.3
Unknown 22.6 56.4 19.9 1.1
Histology (%) <.0001
Adenocarcinoma 16.3 52.7 27.7 3.3
Squamous cell
carcinoma
23.3 51.6 22.0 3.1
Grade (%) <.0001
Well differentiated 19.4 53.4 23.4 3.8
Moderately
differentiated
17.4 54.0 25.4 3.2
Poorly differentiated 17.5 51.9 27.1 3.5
Undifferentiated 12.5 44.8 37.5 5.2
Unknown 29.6 48.4 20.9 1.2
T stage (%) <.0001
T1 17.2 56.3 23.9 2.6
T2 14.9 56.0 26.2 2.9
T3 10.6 54.9 30.9 3.6
T4 19.8 48.7 27.1 4.4
Unknown 46.7 37.5 13.5 2.3
Timing of radiation
therapy (%)
<.0001
None 13.6 55.0 27.6 3.8
Preoperative 29.4 48.4 20.1 2.1
Postoperative 14.7 51.7 29.9 3.7
*Lymph node groups also differed by cancer registry (P< .0001; data not shown).
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We found a significant difference between the LN groups
with regards to all-cause (Wilcoxon test, P < .0001;
Figure 2, A) and cancer-specific mortality (Wilcoxon test,
P ¼ .004; Figure 2, B).
Cox Proportional Hazards Regression Model
After generating log-log survival plots (not shown) for all-
cause and cancer-specific mortality, we noted the plots to beThe Journal of Thoracic and Carelatively homogenous over time; there was only a minor de-
viation at later periods of follow-up. Therefore, we chose to
exclude the time-dependent interaction term from our final
model because including the term would have significantly
increased the complexity of our analysis, with little improve-
ment in accuracy.
When modeled as a continuous variable, we noted a sig-
nificant relationship between all-cause (P< .0001) and can-
cer-specific mortality (P ¼ .0002): survival improved as the
number of LNs examined increased. To determine whetherrdiovascular Surgery c Volume 139, Number 3 615
FIGURE 2. Overall (A) and cancer-specific (B) survival Kaplan-Meier curves for each lymph node (LN) group. Survival with 95% confidence interval (CI)
at each year of follow-up for each LN group provided in the table below each graph.
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TABLE 3. Cox proportional hazards regression models for all-cause
and cancer-specific mortality
Variable
All-cause mortality
HR (95% CI)*,y
Cancer-specific
mortality HR
(95% CI)*,y
Number of lymph
nodes examined*
0 1.00 (reference)a 1.00 (reference)a
1–11 0.98 (0.88, 1.08)a 0.99 (0.88, 1.11)a
12–29 0.85 (0.75, 0.95)b 0.90 (0.79, 1.02)a
 30 0.55 (0.42, 0.72)c 0.58 (0.44, 0.78)b
Age at diagnosis (y)
<50 1.00 (reference)a 1.00 (reference)a
50–64 1.14 (0.99, 1.31)a 1.08 (0.94, 1.25)a
 65 1.51 (1.32, 1.73)b 1.37 (1.19, 1.58)b
Race
Caucasian 1.00 (reference)a 1.00 (reference)a
African-American 1.24 (1.08, 1.44)b 1.23 (1.05, 1.44)a
Other 0.93 (0.76, 1.12)a 1.00 (0.82, 1.23)a
Gender
Female 1.00 (reference)a 1.00 (reference)a
Male 1.21 (1.10, 1.35)b 1.21 (1.09, 1.35)b
Tumor location in
esophagus
Proximal 1.00 (reference)abc 1.00 (reference)a
Midthoracic 1.23 (0.99, 1.51)ac 1.29 (1.02, 1.62)b
Distal 0.99 (0.81, 1.22)bc 1.01 (0.81, 1.27)a
Overlapping 1.20 (0.91, 1.58)c 1.21 (0.90, 1.64)a
Unknown 1.19 (0.89, 1.58)c 1.16 (0.84, 1.60)a
Histology
Adenocarcinoma 1.00 (reference)a 1.00 (reference)a
Squamous cell
carcinoma
1.13 (1.02, 1.25)b 1.12 (1.01, 1.25)b
Grade
Well differentiated 1.00 (reference)a 1.00 (reference)a
Moderately
differentiated
1.58 (1.30, 1.91)b 1.82 (1.45, 2.29)b
Poorly differentiated 1.99 (1.65, 2.41)c 2.40 (1.92, 3.01)c
Undifferentiated 2.04 (1.51, 2.77)c 2.41 (1.71, 3.39)c
Unknown 1.28 (1.02, 1.62)d 1.49 (1.14, 1.96)d
T stage
T1 1.00 (reference)a 1.00 (reference)a
T2 2.16 (1.87, 2.49)b 2.52 (2.14, 2.96)b
T3 2.93 (2.58, 3.34)c 3.43 (2.96, 3.98)c
T4 3.78 (3.26, 4.39)d 4.60 (3.90, 5.43)d
Unknown 2.22 (1.90, 2.58)b 2.47 (2.08, 2.95)b
Timing of radiation
therapy
None 1.00 (reference)a 1.00 (reference)a
Preoperative 0.74 (0.67, 0.81)b 0.75 (0.68, 0.83)b
Postoperative 0.90 (0.81, 0.99)c 0.95 (0.85, 1.06)a
HR, Hazard ratio; CI, confidence interval. *Hazard ratios adjusted for cancer registry
(data not shown) yHazard ratios that do not share a letter (a, b, c) are significantly dif-
ferent (P< .05); hazard ratios that share a letter are not significantly different.
Groth et al General Thoracic Surgery
G
T
Sor not there was a threshold (above which there is no signif-
icant improvement in morality), we also modeled the associ-
ation between the LN groups and mortality. Only patientsThe Journal of Thoracic and Cawho had at least 12 LNs evaluated had significantly lower
all-cause and cancer-specific mortality rates than patients
who had no LNs examined. Patients with more than 30
LNs had the lowest mortality rates (Table 3). Even after ex-
cluding patients who died within 30 days of esophagectomy,
our results were unchanged.
Our multivariate assessment also revealed that patients
who were 65 and older, men, or African-Americans and pa-
tients with squamous cell carcinomas and higher-grade and
more advanced T-stage tumors had worse all-cause and can-
cer-specific mortality (Table 3). Patients with midthoracic
tumors (where squamous cell carcinomas predominate)
had worse cancer-specific mortality and a nonsignificant
trend toward worse all-cause mortality as compared with
other tumor locations. Neoadjuvant radiation therapy had
a protective effect. Compared with patients who did not un-
dergo radiation therapy, patients who had adjuvant radiation
therapy had slightly lower all-cause mortality rates; how-
ever, cancer-specific mortality was not improved (Table 3).
Due to concern for multicollinearity, we did not include
the number of positive LNs in our multivariate survival
model. Instead, we stratified our results by LN positivity
to adjust for the confounding influence of LN status on sur-
vival and found that our results were unchanged (data not
shown).
We assessed for interactions between LN counts and
other tumor characteristics. The test for heterogeneity
across T-stage strata was significant (P < .0001). How-
ever, after stratifying our analysis by T stage (to ensure
that our pooled estimates were consistent across these
strata), our results were unchanged. We did not find signif-
icant heterogeneity across histology strata (P ¼ .16), and
our results were unchanged when we stratified by histol-
ogy. We found significant heterogeneity across tumor
grade strata (P ¼ .002). Our results were unchanged
when we stratified our analysis for moderately differenti-
ated and poorly differentiated tumors. We were unable to
stratify by all tumor grades as few patients with more
than 30 LNs examined had well-differentiated (n ¼ 12)
or undifferentiated tumors (n ¼ 7).
Our results confirmed our hypothesis that patients who
had neoadjuvant radiation therapy had significantly lower
(P<.0001) LN yields (median, 5; range, 0–71) than patients
who did not (median, 7; range 0–90). Though the test for het-
erogeneity across timing of radiation strata was significant
(P< .0001), stratifying our results by timing of radiation
therapy did not change our study findings: (1) there is an as-
sociation between higher LN counts and reduced mortality
and (2) patients with a least 30 LNs examined had the lowest
mortality rates.
LN Counts and Nodal Staging
We plotted the probability of finding at least 1 positive LN
by the number of LNs examined using locally weighted leastrdiovascular Surgery c Volume 139, Number 3 617
FIGURE 3. Locally weighted least squares smooth of the percentage of
patients with at least 1one positive lymph node as function of the number
of lymph nodes examined.
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largest (indicative of the greatest impact on finding LN me-
tastasis) when at least 3 LNs were examined, as compared
with examination of less than 3 LNs (adjusted odds ratio
[OR] 2.97; 95% confidence interval [CI]: 2.32–3.79). The
probability of finding a positive LN reaches an asymptote
near 15 LNs examined, which suggests that higher LN yields
do not improve the accuracy of nodal staging (Figure 3). In-
deed, patients who had 12 to 29 LNs examined were signif-
icantly more likely to have LN metastasis detected than
patients with 11 or fewer LNs examined (OR 1.69; 95%
CI: 1.44–1.98). There was no significant difference in the
odds of detecting LN metastasis between patients who had
30 or more LNs examined and patients who had 12 to 29
LNs examined (OR 0.93, 95% CI: 0.63–1.37).DISCUSSION
Using a large US population-based cancer registry, we
demonstrated that the number of pathologically examined
LNs removed at the time of esophagectomy has a significant
association with all-cause and cancer-specific mortality. We
were not able to ascertain a threshold of mortality benefit;
survival was maximized when more than 30 LNs are exam-
ined, independent of patient characteristics, tumor character-
istics, and use of neoadjuvant radiation therapy. Though the
inclusion criteria and methodologies are different, our re-
sults corroborate other recently published single-institution,
international, and population-based studies that have exam-
ined the association between LN counts and survival in
esophageal cancer patients.5-9
Bollschweiler and colleagues6 performed a single-institu-
tion retrospective review of 213 esophageal cancer patients
who had surgical resection with curative intent (predomi-
nately en bloc esophagectomy and 2-field lymphadenec-
tomy) and determined that at least 16 LNs should be
examined. As compared with patients who had 16 to 30
LNs examined, they did not find an improvement in survival618 The Journal of Thoracic and Cardiovascular Surgif more than 30 LNs were examined; however, only 7 pa-
tients with more than 30 LNs examined had 4 or more years
of follow-up.
Altorki and colleagues5 reviewed their experience of 264
patients who underwent esophagectomy without neoadju-
vant therapy.5 Patients were divided into quartiles based
on the number of LNs examined. They found that higher
LN counts were associated with improved survival. Similar
to our results, they found that patients with more than 26
LNs examined had the most favorable survival rates. Unlike
our results, however, their results differed based on LN sta-
tus. In patients with N0 disease, survival was maximized
when 26 LNs were examined. Patients with N1 disease,
however, required examination of more than 40 LNs to
achieve a significant improvement in survival as compared
with patients who had 16 or fewer LNs examined. After
stratifying by LN positivity, we did not find a difference in
the number of LNs that should be examined; survival was
maximized when more than 30 nodes were examined, re-
gardless of LN status. Differences in our patient population,
sample size, inclusion criteria (we did not exclude patients
underwent neoadjuvant radiation therapy), and variables in-
cluded in our multivariate survival model may explain this
discrepancy between our results and the results of others.
The results of a retrospective, international, multi-institu-
tional study of 2303 patients who underwent R0 resection of
esophageal cancer were recently published by Peyre and as-
sociates.8 Similar to other studies, they excluded patients
who had neoadjuvant or adjuvant therapy. They dichoto-
mized patients into LN groups using thresholds of 1 to 60
LNs examined (ie, 1 vs>1, 2 vs>2, etc) and found
that the chi-square for the LN variable in a Cox proportional
hazards regression model was maximized (suggestive of the
greatest effect) between 23 and 29 LNs examined. Similar to
our results, however, they did not identify a threshold LN
count above which there was no incremental improvement
in survival; survival continued to improve as more LNs
were examined.
Recently, Greenstein and colleagues7 utilized the SEER
database (1988–2003) to assess the association between
negative LN counts and survival in patients with node-neg-
ative (AJCC stage I and IIa) esophageal carcinoma who did
not have neoadjuvant radiation therapy. Unlike our study,
they found heterogeneity across T-stage strata. For patients
with T1 disease, they determined that higher LN yields
(more than 18 LNs) were necessary to maximize survival.
However, for patients with T2 or T3 disease, examination
of 11 to 17 LNs provided the same survival advantage as ex-
amination of more than 18 LNs. Differences in methodology
may explain this discrepancy. Greenstein and colleagues7
focused on number of negative LNs examined; we focused
on total LN counts. They restricted their analysis to patients
with localized disease; we included patients with localized
and regional disease. They excluded patients who hadery c March 2010
Groth et al General Thoracic Surgery
G
T
Sneoadjuvant therapy; we did not. In addition to adenocarci-
nomas and squamous cell carcinomas, they also included
other histologies (small cell carcinomas, lymphomas, mela-
nomas, and sarcomas). We chose to exclude these tumors as
they likely have different biologic behavior than adenocarci-
nomas and squamous cell carcinomas of the esophagus.
In contrast to many of these previous studies,5,7,8 we
chose to include patients who had neoadjuvant radiation
therapy because it is becoming the standard of care for
locally advanced esophageal carcinoma.10 Therefore, our re-
sults may be more generalizable to today’s esophageal can-
cer patient. We found that the esophageal specimens from
patients who complete neoadjuvant radiation therapy have
significantly fewer LNs than patients who did not, which
is not surprising as radiation therapy may cause lymphocyte
depletion and stromal fibrosis resulting in significantly
smaller (or even ablated) LNs.11 Nonetheless, LN counts
are still important in patients who have preoperative radia-
tion therapy; radiation therapy should not be an excuse for
not finding LNs in an esophagectomy specimen.
Though our results indicate that a large number of LNs
should be examined to maximize all-cause and cancer-
specific mortality, it does not provide insight into the debates
regarding the optimal esophagectomy approach (ie, transhia-
tal, Ivor Lewis, and en bloc) or the optimal extent of lympha-
denectomy (2-field vs 3-field). Our results simply indicate
that 30 or more LNs should be examined (regardless of the
operative technique).
Though it is clear that LN counts are associated with sur-
vival, the underlying mechanisms behind this association are
poorly understood. There are a number of possibilities. One
such mechanism is improved local tumor control: clearing
more LNs (to ensure removal of occult or overt metastasis)
may reduce local recurrence rates. Indeed, recurrent disease
is almost uniformly fatal.12 Unfortunately, SEER does not
collect recurrence data, preventing us from further analyzing
this potential association.
More accurate cancer staging is another potential mecha-
nism. By removing more LNs, the risk of failing to detect LN
metastasis (which may prevent patients from receiving opti-
mal cancer therapy) is lessened. However, we demonstrated
that the number of LNs needed to optimize cancer-specific
mortality (30 or more LNs) is not the same as the number
need to maximize the likelihood of detecting LN metastasis
(about 15 LNs). Our findings are similar to a recursive par-
titioning analysis of data from 336 patients who had esoph-
agectomy at the Memorial Sloan-Kettering Cancer Center;
examination of 18 LNs was recommended to optimize the
accuracy of cancer staging.13 This discordance between
the number of LNs that should be examined to optimize sur-
vival and the number needed to optimize cancer staging has
been replicated in the colorectal cancer literature. According
to current guidelines, at least 12 LNs should be examined in
colorectal cancer patients who undergo colectomy.14 InThe Journal of Thoracic and Caa study using the SEER-Medicare database, Wong et al15
demonstrated that removing 12 LNs did not increase the ac-
curacy of colorectal cancer staging.
The discordance between the number of LNs needed to
optimize survival and the number needed to accurately stage
patients suggests that potential factors are present in both
esophageal and colorectal cancer patients (and likely pa-
tients with other malignancies as well) that confound the as-
sociation between LN counts and survival. Such factors
include: (1) surgeon factors (training, esophagectomy vol-
ume, and oncologic quality of the esophagectomy and lym-
phadenectomy); (2) pathologist factors (skill and diligence
looking for LNs); (3) hospital factors (esophagectomy vol-
ume, teaching status, and global quality of patient care);
(4) patient factors (ability to mount an immune response to
cancer thereby making it easier to find LNs); or (5) other
(unrecognized) factors.
There are several limitations of our study, some of which
are inherent limitations of SEER. In particular, the SEER
cancer registries do not collect information on several
factors associated with survival, such as performance sta-
tus,16 comorbidities,17 use of chemotherapy,18 completeness
of resection,19 margin length,20 time to local recurrence,19
weight loss (more than 10%),21 and surgeon and hospital
esophagectomy volume.22,23 Therefore, we could not adjust
for these covariates in our model. In addition, SEER does not
mandate endoscopic verification of tumor location. As
a result, there is a potential for misclassification. However,
when we stratified patients into broader tumor location
groups (cervical, thoracoabdominal, and overlapping), our
results were unchanged, indicating that misclassification of
tumor location was not a significant source of error.
Finally, we restricted our analysis to only include adeno-
carcinomas and squamous cell carcinomas to reduce the
confounding influence of other histologies (and their vary-
ing biologic behavior) on our results. As a result, our results
may not be generalizable to other histologies.
We believe our use of a large population-based cancer
registry, inclusion of patients representative to today’s
esophageal cancer patients (ie, those who had neoadjuvant
therapy), and demonstration of consistent results across
a variety of strata adds to the growing body of evidence in
the literature regarding the association between LN counts
and survival. Additional studies are needed to ascertain the
underlying mechanisms behind LN counts and survival.CONCLUSION
Though the underlying mechanism has yet to be eluci-
dated, the number of LNs examined in esophageal cancer
patients who undergo esophagectomy is a significant
independent determinant of all-cause and cancer-specific
mortality, even among patients who complete neoadjuvant
radiation therapy. Therefore, LN counts after esophagealrdiovascular Surgery c Volume 139, Number 3 619
General Thoracic Surgery Groth et al
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Sresection should be a central feature of surgical quality
assessment.
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